85 related articles for article (PubMed ID: 19329412)
1. Analysis of published economic evaluations of angiotensin receptor blockers.
Theodoratou D; Maniadakis N; Fragoulakis V; Stamouli E
Hellenic J Cardiol; 2009; 50(2):105-18. PubMed ID: 19329412
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
[TBL] [Abstract][Full Text] [Related]
3. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.
Miller LA; Wade R; Dai D; Cziraky MJ; Ramaswamy K; Panjabi S
Curr Med Res Opin; 2010 Jun; 26(6):1307-20. PubMed ID: 20370377
[TBL] [Abstract][Full Text] [Related]
5. A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients.
Kourlaba G; Gialama F; Tsioufis K; Maniadakis N
Int J Cardiol; 2016 Oct; 221():60-74. PubMed ID: 27404671
[TBL] [Abstract][Full Text] [Related]
6. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
Belsey JD
J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
[TBL] [Abstract][Full Text] [Related]
7. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
Zaiken K; Hudd TR; Cheng JW
Ann Pharmacother; 2013 May; 47(5):686-93. PubMed ID: 23585649
[TBL] [Abstract][Full Text] [Related]
8. Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis.
Mazza A; Sacco AP; Townsend DM; Bregola G; Contatto E; Cappello I; Schiavon L; Ramazzina E; Rubello D
Biomed Pharmacother; 2017 Jun; 90():665-669. PubMed ID: 28415046
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
[TBL] [Abstract][Full Text] [Related]
10. AT1 receptor blockers--cost-effectiveness within the South African context.
Anderson AN; Wessels F; Moodley I; Kropman K
S Afr Med J; 2000 May; 90(5):494-8. PubMed ID: 10901822
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
12. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
Ekman M; Bienfait-Beuzon C; Jackson J
J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
[TBL] [Abstract][Full Text] [Related]
14. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
Michel MC; Foster C; Brunner HR; Liu L
Pharmacol Rev; 2013 Apr; 65(2):809-48. PubMed ID: 23487168
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
16. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
Keiding H; Hildebrandt P; Burke T; Carides GW
Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
Signorovitch J; Zhang J; Wu EQ; Latremouille-Viau D; Yu AP; Dastani HB; Kahler KH
Curr Med Res Opin; 2010 Apr; 26(4):849-60. PubMed ID: 20141381
[TBL] [Abstract][Full Text] [Related]
19. A Cost-Effectiveness Analysis between Amlodipine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention among Hypertension Patients in China.
Wu Y; Zhou Q; Xuan J; Li M; Zelt S; Huang Y; Yin H; Huang M
Value Health Reg Issues; 2013 May; 2(1):75-80. PubMed ID: 29702856
[TBL] [Abstract][Full Text] [Related]
20. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]